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Canine parvovirus 2 (CPV-2) is an extremely contagious virus that causes high morbidity 
and mortality in canines, especially pediatrics.  The virus was first discovered in 1978, while it 
was in the midst of a global pandemic.  Since this time, it has remained at the forefront of 
veterinary medicine.  Canine parvovirus 2 causes acute hemorrhagic enteritis and myocarditis, 
both of which are very difficult for canines to recover from, making it one of the leading causes 
of death.  Viral shedding occurs through the feces of infected animals that occurs during the 
incubation period, and it spreads through contact with individuals and fomites.  Canine 
parvovirus 2 is a robust virus, having the ability to resist many disinfectants and survive in 
contaminated soil for up to 5 months or longer.  Additionally, there are ongoing issues that 
include the failure of available vaccines in providing adequate protective immunity and the lack 
of some in-clinic diagnostic assays to positively identify the virus.  New strains of the virus, such 
as CPV-2c, have evolved over the last 30 years, and they have also spread all over the world.  All 
of these factors have led to the inability to contain the virus and its disease manifestation.  The 
purpose of this report is to understand how strains of canine parvovirus have emerged over the 
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Chapter 1 - Introduction to Canine Parvovirus 
Canine parvovirus (CPV-2), commonly known as “parvo”, causes acute hemorrhagic 
enteritis in puppies and adult dogs.  In Latin, the word “parvo” means small (Nandi et al., 2010).  
It is a significant veterinary disease because of the high morbidity, mortality, transmissibility, 
and resistance to sanitation. This report will focus on how new strains of canine parvovirus have 
emerged and review the resultant impacts on canine health.  Before focusing on this, Chapter 1 
will first review the most important features of canine parvovirus, including the molecular 
structure, epidemiology, clinical disease presentation, diagnostics, treatment, and prevention 
strategies.  There are challenges in preventing this disease that will also be discussed. 
Taxonomy  
Viruses have their own system of classification, separate from that of cellular organisms 
(Kuhn, 2017).  Canine parvovirus 2 is in the realm Monodnaviria, the kingdom Shotokuvirae, the 
phylum Cossaviricota, the class Quintoviricetes, and the order Piccovirales (National Center for 
Biotechnology Information, 2020). It has been classified in the family Parvoviridae, which is 
divided into two subfamilies: Parvovirinae and Densovirinae.  Parvovirinae is further divided 
into five genera: Amdovirus, Bocavirus, Dependovirus, Erythrovirus, and Protoparvovirus, 
formerly known as Parvovirus (Halder et al., 2012; Yip et al., 2020).  For CPV-2, it is 
considered part of the genus Protoparvovirus and the species Carnivore protoparvovirus 1 
(Battilani et al., 2019). 
Characterization of canine parvovirus 
Canine parvovirus 2 is a non-enveloped, single-stranded DNA virus, and is suspected to 
have evolved from feline panleukemia virus (FPV) (Halder et al., 2012).  The evolution of CPV-
2 will be further discussed in Chapter 2.  The virus is small in size (approximately 25 nanometers 
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in diameter) and icosahedral in shape (Halder et al., 2012; Decaro et al., 2012).  An icosahedron 
is described in geometry as a shape that has 20 sides.  The virus has a linear, single-stranded, and 
negative-sense DNA genome with approximately 5,000 nucleotide bases (Halder et al., 2012).   
Canine parvovirus genomic organization 
The genomic structure of parvovirus includes two open reading frames (ORFs) with 
palindromic sequences that are 120-550 nucleotides in length, which fold into hairpin structures 
(Halder et al., 2012).  These are critical for replication.  The sequence of the 5’ end encodes for 
proteins that are not structural (NS), which are important for packaging and genome replication.  
There are two nonstructural proteins (NS1 and NS2).  The 3’ end encodes for the two structural 
viral proteins (VP1 and VP2) that form the capsid (Halder et al., 2012).  Viral protein 1 is the 
primary cause of viral infectivity.  Viral protein 2 is the main component in the capsid of CPV-2, 
and the slight changes in the amino acid sequence are what define the three variant strains: CPV-
2a, CPV-2b, and CPV-2c.  Canine parvovirus 2b and Canine parvovirus 2c are defined by amino 
acid changes in VP2.  Residue 426 of the VP2 sequence is the location that with a single amino 
acid change distinguishes it as either CPV-2b or CPV-2c.  For strains CPV-2 and CPV-2a, 
asparagine is present at residue 426, but for CPV-2b, it is aspartic acid and for CPV-2c, it is 
glutamic acid (Markovich et al., 2012).  These single amino acid changes greatly affect 
monoclonal antibody binding to the viral capsid as well as polyclonal antibody binding 
(Markovich et al., 2012). 
The capsid structure that contains these nonstructural and viral proteins is important to 
the virus’s pathogenicity as well.  The surface of the capsid has a long, raised region, referred to 
as a “spike” on the threefold axes of the capsid (Halder et al., 2012).  This threefold axis of the 
capsid is the most antigenic region on the capsid structure and is home to epitope A, which is 
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home to many of the residues that change between parvovirus species and CPV-2 variant strains 
(Halder et al., 2012).  These will be discussed in more detail throughout Chapters 1 and 2.  The 
threefold axes is also the target binding location for monoclonal and polyclonal antibodies 
(Halder et al., 2012).  There is also a deep canyon that surrounds some cylindrical structures at 
the fivefold axes, and lastly, there is a deep dimple at the twofold axes of the capsid (Halder et 
al., 2012).   
History and epidemiology 
In the mid to late 1970’s, a novel virus emerged that caused acute hemorrhagic enteritis 
and myocarditis in canines known today as canine parvovirus type 2 (CPV-2).  The virus was 
officially isolated and identified in 1978 in the United States (Parrish et al., 1988).  The virus 
swept through the entire canine population in the Americas, Asia, Australia, Europe, and New 
Zealand so quickly and devastatingly that a pandemic was declared from 1979-1980 (Parrish et 
al., 1988).  Dog sera from Greece and Belgium were later tested for antibodies, and the results 
showed that CPV-2 had emerged in these countries between 1974 and 1976, but in Australia, 
Japan, and the United States only sera from 1978 and later tested positive for CPV-2 (Parrish et 
al., 1999).  Ever since 1978, CPV-2 has been omnipresent globally.  In 1979, wild coyotes 
became widely infected throughout the United States as well (Parrish et al., 1999).  The first 
variant strain of CPV-2, CPV-2a, emerged in 1979 in the United States.  A few years later, the 
next variant strain, CPV-2b, emerged in the United States in 1984.  Several years later, the last 
prominent variant strain, CPV-2c, emerged in Italy in 2000.   
It has been nearly 45 years since the CPV-2 virus first emerged.  In that time, three new 
variant strains have emerged, and the four strains have disseminated throughout 42 countries, on 
six continents worldwide (Decaro et al., 2012; Miranda et al., 2016).  The original CPV-2 strain 
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is now much less common than the three antigenic variant strains but does still cause cases of 
disease to this day.  The variant strains are dominant in fluctuating proportions in countries 
worldwide.  Awareness about the dominant variant strain depends on how actively CPV-2 is 
being monitored or how many CPV-2 research studies are actively taking place in a given place 
at a given time.   
Canine parvovirus 2a has been shown to be present in 37 countries and to be the main 
variant in Asia, Australia, and Europe, as well as the only variant present in New Zealand, 
Nigeria, Hungary, Czech Republic, Slovenia, and Romania (Battilani et al., 2019: Decaro et al., 
2007; Decaro et al., 2011; Decaro et al., 2012; Miranda et al., 2016).  Canine parvovirus 2b has 
been found across five continents, 31 countries, and it is the dominant variant strain in Africa, 
many Asian countries, many African countries, Ireland, the U.K., and the U.S. (Battilani et al., 
2019).  Canine parvovirus 2a and canine parvovirus 2b were equally present in Belgium, 
Switzerland, and Austria (Truyen et al., 2000).  Canine parvovirus 2c was found in 21 countries 
across the world and determined to be the most prominent variant strain in many European 
countries and South America (Battilani et al., 2019). 
Incidence 
Canine parvovirus 2 infects canines of all ages, but particularly pediatrics (younger than 
12 weeks) and juveniles (12 weeks to 6 months) that are between 6 weeks old and 4 months old 
(Serpell et al., 2016).  This is due to insufficiencies in immunological protection as well as being 
an ideal host because of their rapid growth and development.  Canine parvovirus 2 can cause 
100% morbidity in canine patients of all ages, with mortality rates at about 90% in pediatrics and 
juveniles and 10% in adults (Tosaris, 2018).  Crossbred canines tend to be less susceptible to the 
virus than purebreds (Houston et al., 1996).  The virus causes acute hemorrhagic enteritis, and in 
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many cases, causes subacute myocarditis (Decaro et al., 2012).  Many patients succumb to a 
secondary infection due to the damage to the immune system, primarily the bone marrow and 
white blood cells that act as a primary line of defense against infection.  White blood cell (WBC) 
counts can typically drop as low as 2,000-3,000 cells/L of blood.  Often, patients may succumb 
to malabsorption due to the significant damage to the small intestines and the loss of their 
nutrient absorption capabilities.  The small intestines are the primary site of all nutrient 
absorption from food, so when they are severely damaged, malabsorption occur.   
In some cases of CPV-2, myocarditis can occur in patients, usually pediatrics 3 months of 
age or younger, and they can succumb to subsequent heart failure (Hayes et al., 1979).  Often 
when puppies survive the first 3-4 days of the viral infection, they will make a full recovery in 
about a week.  Around 70-90% of patients with enteritis from CPV-2 can survive with the 
correct supportive care and derive long term, if not lifelong, immunity following recovery 
(Gallagher, 2020).   
Pathogenesis 
Parvovirus is typically transmitted through the fecal-oral route from contact with feces of 
an infected animal or through the oronasal route through contact with a fomite (Goddard et al., 
2010).  Infected canines shed the virus in their feces starting at around 4-5 days post exposure, 
and they can continue to shed the virus for up to 3-4 weeks following subclinical or clinical 
infection (Goddard et al., 2010).  Once the virus has been ingested, it travels to the lymph nodes 
of the gastrointestinal tract, the lymph nodes of the throat, or the tonsils where it incubates and 
multiplies for about two days.  Once it has replicated, the virus spreads to the bloodstream.  From 
there it travels to the bone marrow, targeting the WBCs as well as to both the large and small 
intestines, where it replicates in the intestinal villi and later causes atrophy of the villi.  In the 
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small intestines, the virus eventually critically damages the enterocytes of the crypts of the 
intestine, otherwise known as the crypts of Lieberkühn (Tosaris, 2018).  This damage and 
necrosis destroy the capability of the intestines to absorb nutrients.  Due to this damage in the 
intestinal lining, blood and protein are leaked into the intestinal lumen, causing anemia and 
protein loss, respectively (Goddard et al., 2010).  In pediatrics, the virus may also travel from the 
lymph nodes to the heart to target the rapidly regenerating cells that are present there.  This is 
what can lead to myocarditis and heart complications like inflammation of heart muscle, poor 
function, and arrhythmias in pediatrics younger than three months of age (Hayes et al., 1979).  
Endotoxins can also be absorbed into the bloodstream from intestinal bacteria, thereby causing 
endotoxemia (Isogai, et al., 1989).  The absorbance of these bacteria can also lead to septic 
shock.   
Parvovirus replicates in cells that rapidly divide, which is why pediatric and juvenile 
canines are more of an ideal host than adults since their cellular regeneration is much higher due 
to growth and development.  Mitotic cells, like those that are rapidly dividing in growing 
canines, are necessary for successful viral replication due to the fact that CPV-2 needs to utilize a 
polymerase to effectively proliferate (Tu et al., 2015).  Canine parvovirus 2 can replicate 
independently, without coinfection, which is also known as an autonomous parvovirus.   
Canine parvovirus 2 replicates inside of the nucleus of the invaded host cell.  This means 
that the virus must navigate through three barriers within the cell in order to reach the nucleus 
and DNA replication machinery: the cellular membrane, cellular plasma, and nuclear membrane.  
The virus attaches to the host’s cell surface receptors in order to invade a cell.  Canine parvovirus 
2 is able to invade the cell via clathrin-dependent endocytic pathway (Tu et al., 2015).  The CPV-
2 VP2 is an “anti-receptor” that binds to the transferrin receptors (TfR) on the cell’s surface and 
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is internalized through the cell membrane via clathrin-coated pits (Tu et al., 2015; Cureton et al., 
2012).  Canine parvovirus 2 is then moved through the endocytic plasma via endosomes at a 
lower pH.  As it gets closer to the nucleus, it is internalized by lysosomes, that continue to 
transport it until it activates phospholipase A2, which releases the virus from the lysosome 
directly into the cytoplasm near the nucleus (Tu et al., 2015).  The VP1 of the virus has a nuclear 
localization signal (NLS) that helps to guide the virus to the nucleus, where it is moved through 
the nuclear pore complex (NPC) and accesses the DNA replication machinery (Tu et al., 2015).   
Once the virus has replicated, the mature virions are moved out of the NPC to continue the life 
cycle, replicating in cells throughout the animal’s body (Tu et al., 2015).   
Gross pathology and histopathology 
For gross pathology in fatal cases, the walls of the intestines are typically thickened and 
discolored (Gallagher, 2020).  Lesions can be observed with multifocal necrosis of the crypt 
epithelium, loss of crypt architecture, and villous blunting and sloughing (Gallagher, 2020). 
Watery, mucoid, or hemorrhagic intestinal contents may also be observed (Gallagher, 2020).  
The Peyer's Patches and mesenteric lymph nodes of the small intestines of affected animals are 
typically enlarged (Decaro et al., 2012).  Abdominal and thoracic lymph nodes often display 
edema and congestion, and the thymus may also be atrophied (Decaro et al., 2012).  For infected 
canines with myocarditis, pale streaks indicating fibrosis can usually be observed in the 
myocardium (Gallagher, 2020).  
For histopathologic lesions of the gastrointestinal tract, hemorrhagic enteritis may be 
observed as well as intranuclear inclusion bodies (Decaro et al., 2012).  The Peyer’s Patches, 
mesenteric lymph nodes, abdominal and thoracic lymph nodes of affected animals may be 
completely depleted of cortical lymphocytes and lymphoid tissue (Gallagher, 2020).  The spleen 
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is also usually completely depleted of cortical lymphocytes and lymphoid tissue (Gallagher, 
2020).  Bone marrow hypoplasia may also be observed (Gallagher, 2020).  
For canines that die of complicating acute respiratory distress syndrome, systemic 
inflammatory response syndrome, endotoxemia, or septicemia, histopathological examination 
may reveal pulmonary edema, alveolitis, and bacterial colonization of the lungs and liver 
(Gallagher, 2020). 
Symptoms and clinical signs 
Canine parvovirus (CPV-2) incubates within the body for 3-7 days after transmission.  
Then, the onset of symptoms begins with lethargy, pain in the abdomen, abdominal distension, 
fever, and loss of appetite.  This quickly leads to weight loss, dehydration, vomiting, and mucoid 
or hemorrhagic (bloody) diarrhea with a distinctive and indecent odor.  Patients sometime 
present with hypothermia (American Veterinary Medical Association, 2021).  Patients may also 
experience septic shock or endotoxemia as a result of bacteria entering the bloodstream or 
endotoxins from disintegrated bacteria entering the bloodstream respectively (American 
Veterinary Medical Association, 2021).  Death usually occurs within the first 2-3 days of clinical 
signs (American Veterinary Medical Association, 2021).   
Pediatric dogs can experience infection in the heart that leads to many complications, 
such as inflammation of the heart muscle (myocarditis), poor cardiac function, and arrhythmias 
(Hayes et al., 1979).  In these rare cases, if an unvaccinated pregnant bitch is infected with the 
virus or if puppies younger than 8 weeks of age from an unvaccinated bitch are infected with the 
virus, then these offspring may develop myocardial infection (Gallagher, 2020).  This leads to 
myocarditis, ultimately resulting in cardiopulmonary failure, usually within 24 hours of clinical 
symptoms (Goddard et al., 2010; Gallagher, 2020). 
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Clinical pathology 
There is diagnostic value in analyzing the blood of canine patients with symptoms of 
CPV-2.  Not only can a WBC count help to support a CPV-2 diagnosis, but leukopenia, 
specifically acute lymphopenia, is a common finding with WBC counts as low as 2,000-3,000 
cells/mL of blood, where the normal reference range is about 6,000-14,000 cells/mL (Markovich 
et al., 2012).  This is an important finding indicating the need to treat as soon as possible; 
however, sometimes the WBC count may appear to be within normal range if an opportunistic 
bacterial coinfection is also present.  Even though the lymphocyte count may be low due to the 
viral infection, neutrophils may be increased in the blood (i.e., neutrophilia) due to the bacterial 
infection.  This would give the false interpretation of a normal WBC count (Markovich et al., 
2012).  This is also an important distinction to be aware of regarding treatment since 
antimicrobials may also be necessary in addition to the supportive care for the viral infection.   
Diagnostics 
There are a handful of different diagnostic assays available for detecting CPV-2 from 
clinically obtained samples.  Enzyme-linked immunosorbent assay (ELISA) and polymerase 
chain reaction (PCR) assay are the most common diagnostic tools that are utilized today for a 
rapid or absolute result, but there are a few other diagnostic assays that are available. 
The ELISA test used for detection of CPV-2 is the most commonly used diagnostic assay 
for in-clinic detection of CPV-2.  The SNAP Canine Parvovirus Antigen Test is an in-clinic rapid 
diagnostic ELISA test used for detection of CPV-2 and takes about 15 minutes to complete.  It is 
a hemagglutination test based on ELISA technology (IDEXX Laboratories, Inc., n.d.).  This 
rapid test is similar to many pregnancy tests.  The design of the test increases the reliability of 
the result by helping to reduce user error in test preparation or interpretation by simplifying the 
10 
process and making the result easy to read in a window-like display. The manufacturer claims 
that no further testing should be needed to reach a definitive diagnosis if a positive result is 
displayed, but that a negative test result does not rule out a diagnosis of parvovirus disease 
(IDEXX Laboratories, Inc., n.d.).  
The PCR assay is the most reliable diagnostic assay available, and it is used for 
confirming in-clinic positive results.  Typically, fecal samples are collected in the clinic and sent 
to a diagnostic laboratory, where viral DNA is amplified for detection of CPV (Tosaris, 2018).  
The PCR assay is sensitive enough to identify and differentiate variant strains that are displayed 
on an agarose gel that utilizes specific primers for each variant strain of CPV (Tosaris, 2018). 
Other diagnostic assays include the Canine Parvovirus-Coronavirus Antigen Test Kit 
(Anigen, Inc.), hemagglutination assays, virus isolation, immunohistochemistry, and electron 
microscopy.  In addition, supportive diagnostic confirmation includes clinical pathological 
findings.  
The Canine Parvovirus-Coronavirus Antigen Test Kit is an in-clinic diagnostic test used 
for the detection of CPV-2.  It is a chromatographic immunoassay that gives a rapid result in the 
clinic, very similar to the SNAP test. The test results can be interpreted about 5-10 minutes 
(BioNote, n.d.).  In-clinic rapid tests like this one can also be confirmed by collecting a sample 
for a PCR assay (Yip et al., 2020). 
Hemagglutination assays (HA) are laboratory-based diagnostic tests that can, but not 
often are, utilized for CPV-2 diagnosis or diagnosis confirmation.  Hemagglutination assays 
require fresh erythrocytes from donor pigs to execute the assay, which can be a roadblock to 
assay execution if there is an issue with the supply of these cells (Decaro et al., 2012).  
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Hemagglutination assays are more efficient than some of the other laboratory-based assays, as it 
can be executed in a 96-well plate and yields results in about four hours (Decaro et al., 2012).   
Virus isolation is a laboratory-based diagnostic tests that can, but not often is, utilized for 
CPV-2 diagnosis or diagnosis confirmation.  This is a cell culture-based assay that requires a 
laboratory with these capabilities, and it is also very time-consuming due to the incubation 
required (Decaro et al., 2012).  Results can take 1-2 weeks to return which makes the use of this 
assay undesirable for emergent cases.  This assay is also considered to have low sensitivity and 
can yield false negatives (Decaro et al., 2012).   
Immunohistochemistry is a laboratory-based diagnostic tests that can, but not often is, 
utilized for CPV-2 diagnosis or diagnosis confirmation.  This assay is also considered to have 
low sensitivity and can yield false negatives (Decaro et al., 2012).   
Electron microscopy (EM) can also be used to examine fecal samples for CPV-2; 
however, this method is considered poorly sensitive and depends on the location of the virus 
within the sample (Decaro et al., 2010).  
Lastly, clinical pathology can be used to support the findings of positive rapid tests. The 
veterinarian can take a blood sample to confirm lymphopenia that is typically associated with 
infection.  Since CPV-2 targets the lymphocytes and bone marrow quickly after infection, a low 
WBC count is a clear co-indicator for the presence of this infection (Cornell University, n.d.).  
The combination of a positive rapid in-clinic test and a low WBC count provides a strong 
indication of CPV infection and the need for immediate medical treatment. 
Treatment 
Treatment of canine parvovirus patients primarily involves supportive care until the 
patient is in recovery.  This care is expensive and not a guarantee that the patient will return to 
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perfect health if they survive.  Infected animals are given intravenous electrolyte fluids to help 
replenish electrolytes, correct dehydration, and combat ongoing fluid loss.  Colloid therapy is 
suggested for animals with severe gastrointestinal protein loss as a bolus and/or continuous 
intravenous administration (Goddard et al., 2010).  Antibiotics are usually provided due to the 
high risk of bacteria invading the intestines and causing secondary infection.  Beta-lactam 
antibiotics are usually prescribed to provide Gram positive and anaerobic bacterial coverage 
(Gallagher, 2020).  If an infection is ongoing, the canine patients are administered an antibiotic 
targeting Gram-negative bacteria.  Antiemetic medication can be recommended as appropriate to 
assist canine patients from continued vomiting, which helps to combat fluid and nutrient losses 
as well as weight loss.  However, antidiarrheals are not recommended because the contaminated 
feces should not be retained within the body.  Sometimes a feeding tube may be placed within 12 
hours of admission to the hospital or clinic so that a continued flow of nutrients occurs with 
decreased disruption from vomiting.  The use of a feeding tube can also assist in combatting 
weight loss.  Gradual reintroduction to food and water once vomiting has ceased is important.  
Oral fecal microbiota transplants from a healthy adult has also been shown to be helpful to 
reduce the recovery time (Periera et al., 2018).  Typically, a successful response to treatment 
takes about 6 days, but in ideal situations, it can be as few as 3 days after the onset of symptoms.  
With the correct combination of treatments, survival rates can reach up to 90% (American 
Veterinary Medical Association, 2021).  The duration of immunity (DOI) following infection 
with CPV is usually life-long (Decaro et al., 2020).   
Prevention 
The main method of prevention of CPV-2 is vaccination.  Vaccination protocols for this 
virus are very important in puppies, and there are core vaccines for CPV-2 available all over the 
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world (Decaro et al., 2020).  Core vaccinations are vaccinations that should be administered to 
all dogs, no matter the circumstances, because the vaccines protect against diseases that have 
severe morbidity and mortality, are highly communicable, and are globally distributed (Decaro et 
al., 2020).  The vaccine is often included as part of a multivalent vaccine that includes canine 
distemper virus, or it is available as a standalone CPV-2 vaccine.  The vaccine is administered to 
canine patients either subcutaneously or intradermally.   
In the U.S., vaccines that are currently licensed for protection against CPV-2 include 
modified live vaccines (MLVs) and inactivated (killed) vaccines.  The inactivated vaccines are 
not usually recommended for canines, unless the animals are pregnant, because they require 
multiple booster injections to provide adequate immunological protection (Decaro et al., 2020).   
The MLVs utilize the original CPV-2 strain of the virus as well as a CPV-2b strain.  The 
MLVs are generally used because they “induce a strong, long-lasting (usually life-long) 
immunity by replicating within the host cells, without producing significant tissue damage or 
clinical signs” (Decaro et al., 2020).  However, this type of vaccine has the potential revert to 
viremia and be shed in the feces.  The ability to replicate in host cells is the main reason why the 
inactivated vaccine is administered to immunocompromised patients or pregnant females instead 
of the live-attenuated vaccine.  Fetuses are very sensitive and susceptible to live modified 
viruses, and so, there is a significant risk that the fetus could be stillborn (Decaro et al., 2020).  
The MLV is given to dogs in a series of three vaccinations in the age ranges of 6-8 weeks, 10-12 
weeks, and 14-16 weeks (Gallagher, 2020).  Modified live vaccines for CPV are characterized by 
their early onset of immunity (OOI) with demonstrated protection as early as three days after 
receiving the vaccine (Decaro et al., 2020).  They are also known for their lengthy duration of 
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immunity (DOI), resulting in protection for as long as 9 years after receiving the vaccine (Decaro 
et al., 2020).   
Because CPV-2 is so hardy in the environment and so easily spread through contact, it is 
very important for owners or handlers to take preventive measures through contact very seriously 
as well.  Owners of puppies must do their due diligence in keeping their animals away from other 
canines until they are vaccinated.  Puppies should be reared and isolated in their own yards, and 
this environment should be clean and sanitized on a regular basis.   
Control 
The control measures of CPV-2 are very important, and good hygiene is the key.  
Veterinary clinics that receive canine patients as well as other communal canine areas, such as 
dog parks or kennels, are critical locations, because they are at the most risk of harboring the 
virus.  Canine parvovirus 2 is highly robust on surfaces and objects, which makes thorough 
sanitization and sterilization very important.  The virus is resistant to many disinfectants, lipid 
solvents, and trypsin, and it can survive on surfaces or contaminated soil for up to 5 months 
(Jacobs et al., 1980; Decaro et al., 2012).  This is one of the properties of CPV-2 that allows it to 
be highly communicable. 
Significant challenges in disease prevention 
Maternal antibody interference is one of the main reasons why CPV-2 vaccine failures 
occur.  Maternally derived antibodies (MDA) are part of passive immunity where pregnant or 
nursing mothers pass their own antibodies to their young via the placenta, colostrum, or milk.  In 
canines, immunoglobulins do not pass through the placenta very well with only about 5-10% 
being transferred to the circulation of the fetus during pregnancy (Decaro et al., 2020).  The 
majority of MDA are transferred to the young through the colostrum, where they are absorbed in 
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the small intestine, through the intestinal epithelium, to the blood.  There is some continued 
transfer of MDA to the young through milk for at least 38 days after parturition, and this 
lactogenic immunity continues to protect the young from infection for limited amount of time 
(Decaro et al., 2020).   
For CPV-2, MDA titers in the blood decline rapidly with the half-life ranging from 8.3-
13.5 days, but they can persist for 13-15 weeks (Parrish et al., 1982).  These MDA can block 
active immunization (vaccination) by neutralizing the viral antigens present in the vaccine, 
thereby preventing seroconversion.  There is a period of time known as the “window of 
susceptibility” or “immunity gap” when the MDA can no longer protect the puppies from 
infection, but they can still interfere with immunization.  This period of time usually lasts 2-3 
weeks and is the reason why the vaccination and booster schedule for CPV-2 requires a series of 
three vaccinations during and after this period of time.   
There have been many strategies suggested to help overcome MDA interference with 
vaccination.  One way to do this is to perform a MDA titration at about 4-6 weeks of age to 
identify the ideal vaccination window of the puppy (Decaro et al., 2020).  This can be performed 
using the hemagglutination inhibition (HI) assay for existing antibody levels, and then, using the 
titer results to extrapolate when the titers may fall low enough for the need of vaccination.  This 
type of testing involves serum collection and transfer to a laboratory with the required 
specialized equipment.  This makes this option fairly impractical until better technology exists.  
Exploring alternate routes of vaccine administration is another strategy that has been 
suggested to potentially overcome MDA interference.  Some experimental vaccines have shown 
some success in overcoming the MDA interference when administered intranasally (Buonavoglia 
et al., 1995).  While the commercially available vaccines are only approved to be administered 
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subcutaneously and intramuscularly, some research has shown that these vaccines are effective at 
circumventing MDA interference when administered orally; however, it is less effective than the 
other routes of administration (Buonavoglia et al., 1995). 
Another challenge in disease prevention is the lack of accuracy of existing diagnostic 
assays and vaccine failures due to the emergence of variant strains of CPV-2.  In Chapter 2, the 
emergence of new strains of CPV-2 will be discussed in detail, including an in-depth discussion 
on the use of available diagnostic assays and the effectiveness of currently licensed vaccines in 
light of the circulation of new strains of CPV-2 in the U.S. and the world.   
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Chapter 2 – Emerging Variant Strains of Canine Parvovirus 
As discussed in Chapter 1, canine parvovirus (CPV-2) is a significant disease in 
veterinary medicine estimated to cause over 250,000 cases of illness in the United States per year 
(Kindred Biosciences, Inc., 2021).  Chapter 2 will review the historical aspects of CPV-2 with 
regard to the emergence of the virus as well as the recent variant strains of CPV-2.  This chapter 
will also discuss important features and impacts of the different strains on canine health. 
Evolution of canine parvovirus 2 and its variant strains 
Canine parvovirus 2 surfaced in the mid to late 1970’s, and while there is some debate 
about exactly when and where it first emerged, the virus sparked a pandemic in canines starting 
in 1978, when it was first officially detected in the United States, with the pandemic ending in 
1979.  It is widely regarded by researchers that CPV-2 evolved as a host range variant from the 
feline panleukopenia virus (FPV) (Yip et al., 2020; Truyen et al., 1995).  Both CPV-2 and FPV 
belong to the genus Protoparvovirus (Yip et al., 2020).  Some researchers suggest, based on 
phylogenetic data, it seems more likely that CPV-2 mutated from a different carnivorous 
parvovirus (Goddard et al., 2010) and that all parvoviruses were derived from a single common 
ancestor (Allison et al., 2012).  Canine parvovirus 2 is 98% genetically similar to FPV (Truyen et 
al., 1995), and Yip et al. (2020) suggested that it may have “jumped the species barrier” in order 
to better replicate in canines.  The virus has become a prime example of how viruses can 
successfully cross species barriers to infect new hosts (Miranda et al., 2014).  This capability has 
led to the significant biodiversity present when evaluating the phylogenetic relationships among 
all parvoviruses that would not have existed if not for multiple cross-species transmission events 
(Miranda et al., 2014).  Canine parvovirus 2 was distinguished as such to differentiate from 
canine parvovirus type 1 (CPV-1), which is distantly related to minute virus of canines, formerly 
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known as MVC (Carmichael et al., 1994).  Interestingly, although CPV-2 is a DNA virus, it 
shows genomic substitution rates that are more similar to RNA viruses, with values of 
approximately 10− 4 nucleotide substitutions per site per year when compared against FPV 
(Decaro et al., 2009).  Canine parvovirus 2 became established by gaining the ability to bind to 
the canine transferrin receptor (TfR) (Truyen et al., 1996), which has been shown to be crucial 
for the predisposition of host cells to become infected by the virus (Decaro et al., 2012).  Chang 
et al. (1992) determined that there are two important amino acid differences between FPV and 
CPV-2 that determine binding to the TfR.  At the viral protein 2 (VP2) residue 93, lysine 
changed to asparagine in CPV-2, and at the VP2 residue 323, aspartic acid changed to asparagine 
in CPV-2 (Chang et al., 1992).  These changes explain the expansion of the host range and are 
also CPV-2-specific antigenic epitopes (Chang et al., 1992).  However, Miranda et al. (2016) 
points out eight amino acid differences between CPV-2 and FPV.  According to these 
researchers, the VP2 changes at residues 93 and 323 are also joined by a change at residue 103 
from valine in FPV to alanine in CPV-2, and that together, these three amino acid changes were 
necessary to gain the canine host range (Truyen et al., 1995).  The changes at residues 323 and 
375 are also thought to be responsible for determining the pH dependence of hemagglutination 
(HA) (Parrish et al., 1991).  Three additional amino acid changes at VP2 have been proposed to 
cause the virus to lose the ability to replicate in felines: residue 80 changed from lysine in FPV to 
arginine in CPV-2, residue 564 changed from asparagine in FPV to serine in CPV-2, and residue 
568 changed from alanine in FPV to glycine in CPV-2 (Truyen et al., 1994).  Lastly, two more 
amino acid changes occurred at VP2: residue 232 changed from valine in FPV to isoleucine in 
CPV-2 and residue 375 changed from aspartic acid in FPV to asparagine in CPV-2 (Miranda et 
al., 2016).  Due to the advancements in research and technology, the more recent analysis by 
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Miranda et al. (2016) may reflect improved accuracy when compared the analysis by Chang et 
al. (1992).  
Canine parvovirus 2a, -2b, and -2c strains mainly differ by a single different amino acid 
at residue 426 at epitope A of the VP2 (Decaro et al., 2006).  Both CPV-2 and CPV-2a express 
asparagine at residue 426 at epitope A of the VP2 gene, whereas CPV-2b expresses aspartic acid 
and CPV-2c expresses glutamic acid (Yip et al., 2020; Decaro et al., 2006). Canine parvovirus 2b 
and canine parvovirus 2c are thought to be antigenic variants of CPV-2a and are also commonly 
referred to as VP2 426Asp and VP2 426Glu, respectively (Miranda et al., 2016).   
Canine parvovirus 2 can infect a variety of carnivorous species, depending on the strain.  
These species include dogs, coyotes, wolves, cats, bobcats, pumas, raccoons, and more (Miranda 
et al., 2014).  There is concern that felines, in particular, may have an important epidemiological 
role in CPV-2 due to the fact that the species has historically been significant to the virus, and if 
infections continue to occur in this species, they could become a reservoir for new variants of 
CPV-2 (Miranda et al., 2014).   
Today, clinicians and researchers alike are struggling with the vaccine failure associated 
with currently available vaccines to protect canines as well as obtaining an accurate diagnosis 
when CPV-2 is present.  In addition, traditional methods of diagnosing CPV-2 have been shown 
to be poorly sensitive, especially during the latter part of infection (Decaro et al., 2012).   
Canine parvovirus 2 variant strains 
Canine parvovirus 2 
Canine parvovirus 2 was first identified in 1978 in the United States, where it caused 
severe, fatal cases of hemorrhagic gastroenteritis and subacute myocarditis of canines located in 
dog kennels and animal shelters (Decaro et al., 2012).  As a result, thousands of canines died and 
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millions more were infected (Parrish et al., 2005).  It was also discovered globally in Europe, 
Asia, and Australia within 6 months of its discovery in the U.S. (Carter et al., 1987).  This rapid 
spread combined with the devastating loss of canines from CPV-2 resulted in a pandemic being 
declared until 1979 when the first canine parvovirus modified live vaccine was developed.  Due 
to the fact that this virus was completely novel to the world, canines of all ages were highly 
susceptible to this disease, and therefore, this led to high morbidity and mortality.  Canines were 
immunologically naïve, having neither protective antibodies nor immunity against the virus.  
While the virus was devastating for canines, the mutation of FPV that caused its emergence no 
longer allowed the virus to replicate in felines.  The modified live vaccine that was developed for 
CPV-2 was able control further outbreaks; however, the virus was now spread worldwide by 
1980 (Goddard et al., 2010).   
Since the initial discovery of CPV-2, at least 75 variants of this virus have emerged 
(Decaro et al., 2009), but most notably are CPV-2a, CPV-2b, and CPV-2c that are much more 
virulent and pathogenic when compared to the other variant strains (Decaro et al., 2009).  By the 
mid-1980’s, CPV-2 was almost completely replaced in global distribution and disease by strains 
CPV-2a and CPV-2b (Hong et al., 2007).  It has been posed by some researchers that the 
development of host immunity to CPV-2 may have been the catalyst for the gradual emergence 
of CPV-2 antigenic variants (Decaro et al., 2012). 
Canine parvovirus 2a 
Immediately following the CPV-2 pandemic, CPV-2a emerged in 1979 in the United 
States, and then in Japan, Belgium, and Australia (Parrish et al., 1999).  Canine parvovirus 2a 
also spread to Denmark and France between 1979 and 1982 (Parrish et al., 1988).  Infections 
with CPV-2a presented with the same symptoms of acute gastroenteritis and myocarditis as 
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CPV-2.  It was prevalent through the mid 1980’s worldwide, and it also became the most 
common virus in many other carnivores, including wolves, foxes, coyotes, many types of big 
cats, pandas, otters, etc. (Miranda et al., 2016).   
The speed with which CPV-2a spread worldwide and replaced CPV-2 almost entirely 
indicates that this strain had major epidemiological advantages over CPV-2 (Parrish et al., 1988).  
When this strain of CPV-2 emerged, the virus had regained the ability to infect and replicate in 
felines (Truyen et al., 1996).  Canine parvovirus 2a had six amino acid substitutions in the capsid 
protein (VP2) when compared to CPV-2.  Some of these amino acid changes in VP2 were at 
residue 87, where methionine changed to leucine in CPV-2a, at residue 300 where alanine 
changed to glycine in CPV-2a, and at residue 305, where aspartic acid changed to tyrosine in 
CPV-2a (Parrish et al., 1991).  These three amino acid changes gave the virus the ability to 
replicate in cats once again (Miranda et al., 2016).  The other three amino acid changes that 
occurred were located at residue 101, where isoleucine changed to threonine in CPV-2a, at 
residue 297, where serine changed to alanine in CPV-2a, and at residue 555, where valine 
changed to isoleucine in CPV-2a (Truyen et al., 1996).  With these antigenic mutations and 
epidemiological advantages of allowing CPV-2a to efficiently spread across geographical 
locations as well as between host species, this strain is suspected by many researchers to have 
given rise to variant strains CPV-2b and CPV-2c (Organtini et al., 2015).  Recent research shows 
that CPV-2a has been reported in at least 37 countries, and it is co-circulating with CPV-2b and 
CPV-2c in 15 of those countries (Miranda et al., 2016).   
Canine parvovirus 2b 
Canine parvovirus 2b emerged in 1984 in the United States, and it is currently one of the 
more common variants observed in clinical disease today (Miranda et al., 2016).  Recent 
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research shows that CPV-2b has been reported in at least 31 countries, cocirculating with CPV-
2a and CPV-2c in 15 of those countries (Miranda et al., 2016).  Canine parvovirus 2b is 
considered to be an antigenic variant of CPV-2a and differs from it with two amino acid 
substitutions in the major antigenic region (epitope A) of VP2 (Miranda et al., 2016).  The first 
amino acid substitution is at residue 426 from asparagine to aspartic acid in CPV-2b and at 
residue 555 from isoleucine to valine in CPV-2b (Parrish et al., 1985).  The latter substitution is a 
reversion to the original CPV-2 strain, but the substitution at residue 426 is the one that results in 
an altered antigenic epitope that is completely unique to CPV-2b (Parrish et al., 1991).   
Along with the original CPV-2 strain, CPV-2b is the other main strain of the virus that is 
used in the vaccines that are available today (Yip et al., 2020).  This variant of the virus is still 
fairly prevalent today and presents with the same clinical symptoms of acute gastroenteritis and 
myocarditis as CPV-2.   
Canine parvovirus 2c 
The last variant strain of CPV-2 that will be discussed is CPV-2c, which emerged in Italy 
in 2000 and is quickly becoming the most prominent variant strain seen in clinical disease today 
(Yip et al., 2020). After it was first discovered in Italy, CPV-2c spread to Vietnam, Spain, the 
United Kingdom, South America, North America, Portugal, and India (Decaro et al., 2006).  
However, research showed that CPV-2c was isolated in Germany four years prior to its official 
discovery in Italy, meaning that it had been circulating since at least 1996 (Decaro et al., 2007).  
Recent research shows that CPV-2c has been reported in 21 countries, cocirculating with CPV-
2a and CPV-2b in 15 of those countries (Miranda et al., 2016).   
Canine parvovirus 2c is considered by many to be an antigenic variant derived from 
CPV-2a.  As discussed before, they differ by one amino acid change at residue 426, where CPV-
23 
2a expresses an asparagine and CPV-2c expresses a glutamic acid (Markovich et al., 2012; 
Buonavoglia et al., 2001).  As with the other variants of CPV-2, CPV-2c was able to spread 
across many countries and continents rapidly; however, it was able to achieve this more rapidly 
than the others.  Due to this ability, researchers suggest that the VP2 mutation to glutamic acid at 
residue 426 may have provided this variant strain an epidemiological advantage (Markovich et 
al., 2012).  It does not necessarily seem to correlate with this strain’s ability to cause more severe 
disease in naïve or vaccinated dogs, but it does appear to indicate positive selection pressure for 
this particular strain of virus (Markovich et al., 2012).  Researchers also suggest that CPV-2c 
may be capable of replicating more quickly and producing a greater volume of virus to shed and 
transmit to other canines than the other variant strains (Markovich et al., 2012).  Canine 
parvovirus 2c is associated with more severe disease in adult dogs than its predecessors as well 
as more severe infection in fully vaccinated dogs (Decaro et al., 2009; Decaro et al., 2012).  As a 
result, CPV-2c is associated with higher rates of mortality than the other variant strains (Decaro 
et al., 2009).   
Current challenges of variant strains of canine parvovirus 2 
Despite the fact that CPV-2 has been in circulation worldwide for nearly 45 years, there 
are many issues surrounding the diagnosis, control, and prevention of this disease that allow the 
virus to continue to wreak havoc on canine health.  As discussed in Chapter 1, CPV-2 is resistant 
to disinfectants and hardy in surviving in a given environment.  In addition to this, research and 
data have shown that there are many challenges associated with diagnostics and vaccine success.  
If positive cases fail to be detected by diagnostic assays or prevented by vaccination, then proper 
control, sanitization, and prevention measures alone will not effectively control the disease.  This 
is of particular concern with CPV-2c, as dogs infected with this strain would shed the virus in 
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their feces and spread it to other dogs, but as discussed below, it may go undetected due to the 
lack of accuracy of diagnostic assays that are currently available.   
Diagnostic accuracy 
Access to effective and efficient diagnostic assays is crucial in the control and treatment 
of this disease.  While there are very sensitive and accurate laboratory-based diagnostic assays 
available, they are inefficient in an emergency for immediate diagnosis because samples must be 
sent to an offsite laboratory.  These laboratory-based assays are also valuable in confirming 
negative test results from in-clinic assays.  Research has shown that there is a shortfall in the 
sensitivity of readily available, in-clinic diagnostics, which often leads to false negative test 
results (Decaro et al., 2012).  This issue can result in either a delay in the necessary, life-saving 
treatments or a complete failure to administer treatment, both of which can result in fatality. 
Diagnostic assays fall short in accurately detecting different strains of CPV-2.  CPV-2c is 
particularly difficult to detect, and this may be due to its pathogenesis.  Canine parvovirus 2c 
infection can cause high antibody titers within the gut lumen, and these antibodies have been 
shown to interfere with the quantity of viral particles that are shed in the feces (Yip et al., 2020).  
Due to the low sensitivity of the in-clinic assays (Decaro et al., 2012), a heavy viral load may be 
required in order to obtain an accurate diagnosis.  Also, some researchers have shown that CPV-
2c causes feces to become more mucoid in consistency, as opposed to diarrhetic, which has been 
further shown to sequester the viral load within fecal samples (Yip et al., 2020).  Another issue 
specific to the diagnosis of CPV-2c is that the amino acid change at residue 426 to glutamic acid 
has been shown to result in the lack of monoclonal antibody recognition of the epitope associated 
with this amino acid (Hong et al., 2007).  This is a developing problem for the diagnostic assays 
that rely on monoclonal antibodies for specific detection of this strain (Hong et al., 2007).  As 
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new strains of CPV-2 continue to emerge, this will be an important consideration for current in-
clinic assays that rely on monoclonal antibodies for detection. 
Vaccine failure can cause diagnostic failures as well.  While dogs may still become 
infected with CPV-2 after being vaccinated, the antibodies formed from the vaccine may cause 
the viral load during natural infection to be dampened, particularly in fecal samples (Yip et al., 
2020).  This leads to the same issue, where there are not enough viral particles present in the 
feces to accurately detect the virus, leading to a false negative result (Yip et al., 2020). 
 
Vaccine failures 
Vaccine success is important for the prevention and control of disease.  Maternally 
derived antibody (MDA) interference is the major cause of vaccine failure, but administration or 
handling error can cause this as well, and there are also some co-factors that can cause failure as 
well.  The CPV-2 vaccine is a core multivariant modified live vaccine composed of strains CPV-
2 and CPV-2b, and it is recommended for pediatric and juvenile canines as early as possible, 
with two additional boosters.  There are a few different options available for this live-attenuated 
vaccine.  NEOTECH’s NEOPAR® was the first vaccine available in 1979.  Now, Zoetis and 
Merck Animal Health both offer a version of the vaccine as well.  These can either be just 
parvovirus live-attenuated or a combination vaccine with distemper, adenovirus type 1 and 2, 
and canine parainfluenza virus (Gallagher, 2020).  As discussed in Chapter 1, the main issue 
surrounding CPV-2 vaccine success is the interference of MDAs in seroconversion following 
vaccination, since it is administered during the pediatric and juvenile stages when these MDAs 
are still in circulation.   
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In order to try to overcome MDA interference with vaccination seroconversion, pet 
owners must, first and foremost, take care to prevent and control potential exposures during the 
late booster period because this is the time that they are most vulnerable to infection due to low 
MDA titers and potential initial booster failure (Yip et al., 2020).  The next most important 
action pet owners must take is to closely adhere to the recommended booster schedule.  Pet 
owners must continue to be cautious about prevention and control for another couple of weeks 
after the final booster vaccine is administered in order to give their pet’s immune system time to 
acquire the immunity.   
Other causes of vaccine failure may include viral antigenic diversity, high environmental 
viral load challenge, genetic non-responders, breed, other bacterial or parasitic enteric infections, 
and immune incompetence (Yip et al., 2020).  For most vaccines, some other common hurdles to 
vaccine success are inadequate storage temperatures, administration errors, and the strain of virus 
used in the vaccine is mismatched to strain of virus encountered (Yip et al. 2020).  The latter 
point is especially important in the case of CPV-2c because this variant strain is not currently 
present in the vaccines and research suggests that there is a higher rate of vaccine failure when 
this variant strain is encountered. 
There is a long history of CPV-2 infection in canines globally ever since the virus 
emerged in 1978.  Even though there has been a vaccine available since nearly the beginning, 
there are many hurdles in the control and prevention of this virus.  There are new, emerging 
strains, difficulties with readily-available diagnostic assays, and an unacceptable amount of 
vaccine failures.  There is a lot of room for research and improvement moving forward.   
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Chapter 3 – Future Directions and Discussion 
For nearly 45 years, CPV-2 has had a major effect on the health of canines and other 
carnivores worldwide.  Costs for treatment are substantial to pet owners, costing an average of 
$1,200 in supportive care (Kindred Biosciences, Inc., 2021).  There is still a lot of research and 
development to be executed, but as technology continues to evolve, there is hope for developing 
more effective diagnostic and prevention strategies.  This report has outlined the deficiencies that 
currently exist in the diagnosis, control, and prevention of CPV-2, and it has discussed how these 
three issues contribute to an ongoing vicious disease cycle that perpetuates the virus and 
subsequent disease.  This report has also highlighted the absence of an effective treatment for 
CPV-2 infection.   
As mentioned, prevention methods are currently lacking.  The strains used in the 
currently available live attenuated vaccines are the CPV-2 and CPV-2b (Decaro et al., 2020).  
While CPV-2b still circulates worldwide, CPV-2 is not nearly as common anymore.  Canine 
parvovirus 2c has been, and still is, on the rise, and it has shown itself to be more evasive from 
prevention through vaccination.  The fact that it infects and causes disease in both vaccinated 
puppies and adult dogs is an obvious problem (Decaro et al., 2009).  This suggests that there is a 
need for vaccines that include the CPV-2c strain.  Recent technological advances in the 
development of vaccines have been achieved for other viruses, namely coronavirus disease 2019 
(COVID-19) for humans.  It may be advantageous to explore these newer technologies for the 
development of vaccines that include CPV-2c and other emerging variant strains.  Coronavirus 
disease 2019 vaccines are mRNA-based, which is a new type of vaccine, and it is being explored 
for its use in other diseases caused by influenza virus, Zika virus, rabies virus, and 
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cytomegalovirus (Centers for Disease Control and Prevention, 2021).  Therefore, this vaccine 
strategy could be used for canine parvovirus and other impactful veterinary diseases.   
The canine parvovirus has structural properties that allow it to withstand sanitization 
efforts and environmental conditions for extended periods of time.  This is one of the most 
difficult hurdles to overcome, as it is one of the key lines of defense in any disease control.  It is 
pertinent that scientists develop an effective, and yet environmentally friendly, sanitization 
product that can be used in veterinary clinics, kennels, homes, yards, and dog parks.  Future 
research should focus on developing a product that breaks down specific structures of the virus 
since they are what make CPV-2 so hardy.   
Treatment is also an area that has been lacking because there is neither a cure nor a 
particularly effective treatment available.  Supportive care is the only recommendation once a 
canine presents with clinical symptoms.  Unfortunately, this care is both costly and does not 
guarantee survival.  This is a research area that has been lacking for nearly 45 years since CPV-2 
first appeared in canines.  This is not surprising, since research for treatments of gastroenteritis 
that are caused by viruses in humans (other than supportive care) have also not been successful 
(Freedman et al., 2020). 
Most recently, researchers at the animal health company, Kindred Biosciences, Inc., have 
had some critical breakthroughs that could drastically improve both the prevention and treatment 
of CPV-2.  According to a press release that the company issued in September 2020, a pivotal 
efficacy study showed 100% success in preventing the disease in canines challenged with CPV-2 
when administered prophylactically (Kindred Biosciences, Inc., 2020).  In another press release 
issued by the company in June 2021, another pivotal efficacy study yielded 100% success in 
treating the disease when administered once a positive test result was obtained (Kindred 
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Biosciences, Inc., 2021).  Unfortunately, there was very little detail provided regarding the 
design of each study, including the numbers of animals used in each study.  The product, 
currently named “Kind-030”, appears to be based on the use of monoclonal antibodies (Kindred 
Biosciences, Inc., 2021).  The company is pursuing two indications for this product, including 
“prophylactic therapy to prevent clinical signs of canine parvovirus infection" and "treatment of 
established parvovirus infection” (Kindred Biosciences, Inc., 2020; Kindred Biosciences, Inc., 
2021).  According to information released about Kind-030, the product works by binding to 
“critical portions of the virus, preventing the virus from entering into cells” (Kindred 
Biosciences, Inc., 2021).  In April 2021, the USDA approved the efficacy indication for this 
monoclonal antibody (Kindred Biosciences, Inc., 2021).  This product should prove to be 
revolutionary in prevention as it enters the market.  If this product is granted approval for the 
treatment indication, it will be the first time that a targeted and reliable treatment has been 
available for CPV-2.  At this time, there is no information available on whether or not this 
product works equally well for all strains of CPV-2.  The manufacturer also did not disclose 
which strain or strains they utilized for challenge in either pivotal efficacy study.  This 
information will be valuable when they are released to the market, since as discussed previously 
for diagnostic assays and vaccines, what works for one strain of virus may not be as effective for 
the other strains of virus.   
Diagnostic assays are another major area in need of drastic improvement based on the 
research discussed in this report.  The in-clinic, rapid tests utilized in most veterinary clinics 
have been shown to have low sensitivity, and they have also been shown to yield a high 
proportion of false negative test results.  Using technology that is currently available, a new and 
different type of in-clinic assay with better sensitivity could be developed.  Additionally, while 
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PCR is exponentially more sensitive at detecting CPV-2 than nearly all other available diagnostic 
assays, the levels of detection for existing ELISA-based assays show that there could be room for 
improvement.  
There is still more research needed regarding several aspects of the virus itself.  Yip et al. 
(2020) suggested that controlled studies comparing the pathogenicity of all CPV-2 strains should 
be performed, as this information is currently lacking and would provide substantial insight for 
several different areas of research.  There is also a need to perform detailed molecular 
surveillance on all of the emerging CPV-2 strains that are in circulation worldwide (Yip et al., 
2020).  This information would be very beneficial from epidemiological standpoint, as it would 
help guide the analysis of the virus’s distribution pattern data, as well as to inform decisions for 
the strategies for prevention and control in public health.  There is also very little information 
about what co-factors are associated with a higher risk of CPV-2 infection, which could be used 
to reduce infection rates and minimalize the effects of the disease (Yip et al., 2020). 
At the population level, it is important to make advancements in diagnostic assays and in 
control and prevention strategies.  As different strains of CPV-2 are able to efficiently spread, 
mutate, and multiply, it is more likely that the world will see the emergence of new and 
significantly novel strains of CPV-2 in a population that is immunologically naive to these 
strains.   
During the COVID-19 pandemic, BluePearl™ Specialty and Emergency Pet Hospital, 
Inc. reported that from their 90 clinics, they saw a 70% increase in CPV-2 cases relative to 
emergency cases when compared to the prior five years (2015-2019) (BluePearl™, 2020).  
Possible explanations for the increased numbers of CPV-2 cases may be that: 1) there was a rise 
in the supply and/or demand of shelter and foster pets, 2) canines moved through shelter systems 
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so quickly that proper precautions and protocols were not always followed, 3) dog owners took 
their dogs to new outdoor parks or other locations where CPV-2 survived in the environment, 
and 4) the pandemic caused physical or financial barriers to completing vaccination protocols.  
BluePearl™ is in the early stages of analyzing this data, but it does highlight how a major world 
event, like the COVID-19 pandemic, may contribute to the ongoing spread of CPV-2 and the 
potential for the emergence of new strains.  Regardless of the reasons listed above, the ongoing 
transmission and the ability of CPV-2 to readily mutate to variant strains that are undetected by 
current in-clinic diagnostic assays and that cannot be prevented by currently licensed vaccines 
should be areas of future research efforts.  Specifically, diagnostic assays should be quickly 
developed to accurately detect any emergent strains of CPV-2, and new vaccine development 
strategies could be based on those used more recently for human diseases.  A new monoclonal 
antibody treatment shows promise for the future; however, until more data is collected, it is 
unclear whether it will be an effective treatment for disease caused by variant strains of CPV-2. 
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